Avidity Biosciences

Valuation Analysis

About the Company

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Avidity Biosciences Stock at a Glance

Avidity Biosciences (RNA) is currently trading at $13.09 with a market capitalization of $223.9M. The 52-week range spans from $11.95 to $16.77; the current price is 21.9% below the yearly high. Year-over-year revenue growth stands at +1148.3%.

💰 Dividend

Avidity Biosciences currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

2 analysts rate Avidity Biosciences (RNA) on consensus: Strong Buy. The average price target is $25.00, implying +90.99% from the current price. Analyst price targets range from $25.00 to $25.00.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

Trading Data

Related Stocks in the Same Sector

Where can I buy Avidity Biosciences?

Compare top-rated brokers — low fees, trusted providers, fully regulated.